|
Hepatopulmonary syndrome Microchapters |
|
Differentiating Hepatopulmonary syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hepatopulmonary syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatopulmonary syndrome future or investigational therapies |
|
FDA on Hepatopulmonary syndrome future or investigational therapies |
|
CDC on Hepatopulmonary syndrome future or investigational therapies |
|
Hepatopulmonary syndrome future or investigational therapies in the news |
|
Blogs on Hepatopulmonary syndrome future or investigational therapies |
|
Risk calculators and risk factors for Hepatopulmonary syndrome future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Norfloxacin, pentoxifylline, inhaled N(G)-nitro-L-arginine methyl ester, nitric oxide inhalation and methylene blue injection, are among suggested and studied medical treatments for HPS. Most of them failed to show efficacy and hence, non of them yet approved as a standard treatment for HPS.